These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24417261)

  • 1. Irritable bowel syndrome: focus on otilonium bromide.
    Boeckxstaens G; Clavé P; Corazziari ES; Tack J
    Expert Rev Gastroenterol Hepatol; 2014 Feb; 8(2):131-7. PubMed ID: 24417261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.
    Clavé P; Acalovschi M; Triantafillidis JK; Uspensky YP; Kalayci C; Shee V; Tack J;
    Aliment Pharmacol Ther; 2011 Aug; 34(4):432-42. PubMed ID: 21679214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide.
    Forte E; Pizzoferrato M; Lopetuso L; Scaldaferri F
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):25-37. PubMed ID: 22338545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How can we achieve relief of bowel and abdominal symptoms for patients with irritable bowel syndrome with constipation?
    Tack J
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5 Suppl 1):21-6. PubMed ID: 23859757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irritable bowel syndrome.
    Spinelli A
    Clin Drug Investig; 2007; 27(1):15-33. PubMed ID: 17177577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IBS and the role of otilonium bromide.
    Boeckxstaens G; Corazziari ES; Mearin F; Tack J
    Int J Colorectal Dis; 2013 Mar; 28(3):295-304. PubMed ID: 23178991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Otilonium bromide in irritable bowel syndrome: a dose-ranging randomized double-blind placebo-controlled trial.
    Chmielewska-Wilkoń D; Reggiardo G; Egan CG
    World J Gastroenterol; 2014 Sep; 20(34):12283-91. PubMed ID: 25232263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of antispasmodics in the treatment of irritable bowel syndrome.
    Annaházi A; Róka R; Rosztóczy A; Wittmann T
    World J Gastroenterol; 2014 May; 20(20):6031-43. PubMed ID: 24876726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome.
    Glende M; Morselli-Labate AM; Battaglia G; Evangelista S
    Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1331-8. PubMed ID: 12468954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is otilonium bromide globally effective in irritable bowel syndrome?
    Desborough MJ; Ford AC
    Aliment Pharmacol Ther; 2011 Oct; 34(8):1034-5; author reply 1035-6. PubMed ID: 21933208
    [No Abstract]   [Full Text] [Related]  

  • 11. [Intestinal motility disorders and visceral hypersensitivity in irritable bowel syndrome].
    Ropert A; Bouguen G
    Gastroenterol Clin Biol; 2009 Feb; 33 Suppl 1():S35-9. PubMed ID: 19303537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why postprandial abdominal bloating in patients with irritable bowel syndrome does not respond to prokinetics.
    Bortolotti M; Lugli A
    Am J Gastroenterol; 2009 Mar; 104(3):794. PubMed ID: 19209159
    [No Abstract]   [Full Text] [Related]  

  • 13. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM; Shiff SJ; Quigley EM
    Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
    Camilleri M
    Clin Pharmacol Ther; 2012 Jan; 91(1):44-59. PubMed ID: 22071696
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of experimental models in developing new treatments for irritable bowel syndrome.
    Holschneider DP; Bradesi S; Mayer EA
    Expert Rev Gastroenterol Hepatol; 2011 Feb; 5(1):43-57. PubMed ID: 21309671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment options in irritable bowel syndrome.
    Farthing MJ
    Best Pract Res Clin Gastroenterol; 2004 Aug; 18(4):773-86. PubMed ID: 15324713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Otilonium bromide - challenges of putting trial data into practice.
    Hungin AP
    Aliment Pharmacol Ther; 2011 Oct; 34(8):1030; author reply 1031. PubMed ID: 21933204
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy.
    Baldi F; Longanesi A; Blasi A; Monello S; Cestari R; Missale G; Corazziari E; Badiali G; Pescatori M; Anastasio G
    Ital J Gastroenterol; 1991 Nov; 23(8 Suppl 1):60-3. PubMed ID: 1756285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in pharmacological treatment of irritable bowel syndrome.
    Lazaraki G; Chatzimavroudis G; Katsinelos P
    World J Gastroenterol; 2014 Jul; 20(27):8867-85. PubMed ID: 25083060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.